Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Metrics to compare | ALM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALMPeersSector | |
---|---|---|---|---|
P/E Ratio | −41.6x | 19.2x | −0.7x | |
PEG Ratio | - | 0.17 | 0.00 | |
Price/Book | 1.3x | 3.2x | 2.6x | |
Price / LTM Sales | 2.0x | 4.2x | 3.2x | |
Upside (Analyst Target) | 33.1% | 12.7% | 43.2% | |
Fair Value Upside | Unlock | 10.9% | 6.8% | Unlock |